Table 2.
Efficacy and safety endpoints.
| Endpoint | Amantadine | Placebo | sHR or OR (95 %CI) | p-value |
|---|---|---|---|---|
| Median time to recovery in days (95%CI) | 10 (9–11) | 10 (8–11) | sHR 0.94 (0.7–1.3) | 0.7 |
| Median time to death in days (95%CI) | 9 (6–28) | 14 (13–28) | sHR 1.41 (0.5–3.7) | 0.48 |
| Fatalitiesa | ||||
| by day 14 | 8 (8.8%) | 4 (4.7%) | OR 1.94 (0.5–9.18) | 0.374 |
| aOR 1.47 (0.4–5.38) | 0.557 | |||
| by day 28 | 10 (11.1%) | 7 (8.2%) | OR 1.39 (0.45–4.54) | 0.613 |
| aOR 1.13 (0.4–3.23)) | 0.814 | |||
| Intensive carea | ||||
| by day 14 | 8 (8.8%) | 9 (10.6%) | OR 0.81 (0.26–2.52 | 0.800 |
| by day 28 | 8 (8.9%) | 9 (10.6%) | OR 0.82 (0.26–2.55) | 0.800 |
a
Proportions and odds ratios excluding patients lost to follow-up; CI, confidence interval; aOR, adjusted (for age as a linear covariate) odds ratio; OR, odds ratio; sHR, subhazard ratio.